Activation of Toll-like receptor 3 induces apoptosis of oral squamous carcinoma cells in vitro and in vivo

International Journal of Biochemistry and Cell Biology

Volumn 44, Issue 8, 2012, Pages 1266-1275

  Luo, Qingqiong ^a   Hu, Shuiqing ^a   Yan, Ming ^a   Sun, Zujun ^a   Chen, Wantao ^a   Chen, Fuxiang ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Apoptosis; Caspase 3; dsRNA polyinosinic polycytidilic acid; Interferon ; Oral squamous cell carcinoma; Toll like receptor 3

Indexed keywords

BETA INTERFERON; DOUBLE STRANDED RNA; POLYINOSINIC POLYCYTIDYLIC ACID; SMALL INTERFERING RNA; TOLL LIKE RECEPTOR 3;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIGAND BINDING; MALE; MOUSE; MOUTH SQUAMOUS CELL CARCINOMA; NONHUMAN; PROTEIN EXPRESSION;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CASPASE 3; CASPASE 9; CELL LINE, TUMOR; CELL SURVIVAL; ENZYME ACTIVATION; HUMANS; INTERFERON-BETA; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MOUTH NEOPLASMS; POLY I-C; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; TOLL-LIKE RECEPTOR 3; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84861453697     PISSN: 13572725     EISSN: 18785875     Source Type: Journal    
DOI: 10.1016/j.biocel.2012.04.025     Document Type: Article

References (48)

1. Akira S, Takeda K. Toll-like receptor signalling. Nature Reviews Immunology 2004;4:499-511. (Pubitemid 38931765)
2. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006;124:783-801. (Pubitemid 43261452)
3. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001;413:732-8. (Pubitemid 33009951)
4. Aranda FLD, Diaz-Valdes N, Riezu-Boj JI, Bezunartea J, Ruiz M, Martinez M, et al. Adjuvant combination and antigen targeting as a strategy to induce polyfunctional and high-avidity T-cell responses against poorly immunogenic tumors. Cancer Research 2011;71:3214-24.
5. Cai Z, Sanchez A, Shi Z, et al. Activation of Toll-like receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor growth. Cancer Research 2011;71:2466-75.
6. Chawla-Sarkar M, Lindner DJ, Liu YF, et al. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 2003;8:237-49. (Pubitemid 36749609)
7. Chin YE, Kitagawa M, Kuida K, et al. Activation of the STAT signaling pathway can cause expression of caspase 1 and apoptosis. Molecular and Cellular Biology 1997;17:5328-37. (Pubitemid 27357631)
8. Chiron D, Pellat-Deceunynck C, Amiot M, et al. TLR3 ligand induces NF-{kappa}B activation and various fates of multiple myeloma cells depending on IFN-{alpha} production. Journal of Immunology 2009;182:4471-8.
9. Chuang HC, Huang CC, Chien CY, et al. Toll-like receptor 3-mediated tumor invasion in head and neck cancer. Oral Oncology 2012;48:226-32.
10. Chuang JH, Chuang HC, Huang CC, et al. Differential toll-like receptor 3 (TLR3) expression and apoptotic response to TLR3 agonist in human neuroblastoma cells. Journal of Biomedical Science 2011;18:65.
11. De Miranda J, Yaddanapudi K, Hornig M, et al. Astrocytes recognize intracellular polyinosinic-polycytidylic acid via MDA-5. FASEB Journal 2009;23:1064-71.
12. Fujimura T, Nakagawa S, Ohtani T, et al. Inhibitory effect of the polyinosinic-polycytidylic acid/cationic liposome on the progression of murine B16F10 melanoma. European Journal of Immunology 2006;36:3371-80. (Pubitemid 44932738)
13. Gonzalez-Reyes S, Fernandez JM, Gonzalez LO, et al. Study of TLR3, TLR4, and TLR9 in prostate carcinomas and their association with biochemical recurrence. Cancer Immunology Immunotherapy 2011;60:217-26.
14. Gonzalez-Reyes S, Marin L, Gonzalez L, et al. Study of TLR3, TLR4 and TLR9 in breast carcinomas and their association with metastasis. BMC Cancer 2010;10:665.
15. Huang B, Zhao J, Shen S, et al. Listeria monocytogenes promotes tumor growth via tumor cell toll-like receptor 2 signaling. Cancer Research 2007;67:4346-52. (Pubitemid 46815083)
16. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA: A Cancer Journal for Clinicians 2011;61:69-90.
17. Jiang Q, Wei H, Tian Z. Poly I:C enhances cycloheximide-induced apoptosis of tumor cells through TLR3 pathway. BMC Cancer 2008;8:12.
18. Juang SH, Wei SJ, Hung YM, et al. IFN-beta induces caspase-mediated apoptosis by disrupting mitochondria in human advanced stage colon cancer cell lines. Journal of Interferon and Cytokine Research 2004;24:231-43.
19. Kawai T, Akira S. Innate immune recognition of viral infection. Nature Immunology 2006;7:131-7. (Pubitemid 43135878)
20. Kawai T, Akira S. Toll-like receptor and RIG-I-like receptor signaling. Annals of the New York Academy of Sciences 2008;1143:1-20.
21. Kelly MG, Alvero AB, Chen R, et al. TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Research 2006;66: 3859-68.
22. Khan AL, Heys SD, Eremin O. Synthetic polyribonucleotides: current role and potential use in oncological practice. European Journal of Surgical Oncology 1995;21:224-7.
23. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nature Reviews Drug Discovery 2006;5:471-84. (Pubitemid 44136959)
24. Lacour J, Lacour F, Spira A, et al. Adjuvant treatment with polyadenylic-polyuridylic acid (Polya.Polyu) in operable breast cancer. Lancet 1980;2:161-4. (Pubitemid 10084713)
25. Matijevic T, Pavelic J. The dual role of TLR3 in metastatic cell line. Clinical and Experimental Metastasis 2011;28:701-12.
26. McCartney S, Vermi W, Gilfillan S, et al. Distinct and complementary functions of MDA5 and TLR3 in poly (I:C)-mediated activation of mouse NK cells. Journal of Experimental Medicine 2009;206:2967-76.
27. Miyake T, Kumagai Y, Kato H, et al. Poly I:C-induced activation of NK cells by CD8 alpha+ dendritic cells via the IPS-1 and TRIF-dependent pathways. Journal of Immunology 2009;183:2522-8.
28. Morikawa T, Sugiyama A, Kume H, et al. Identification of Toll-like receptor 3 as a potential therapeutic target in clear cell renal cell carcinoma. Clinical Cancer Research 2007;13:5703-9. (Pubitemid 47583894)
29. Morrison BH, Tang Z, Jacobs BS, et al. Apo2L/TRAIL induction and nuclear translocation of inositol hexakisphosphate kinase 2 during IFN-beta-induced apoptosis in ovarian carcinoma. Biochemical Journal 2005;385:595-603. (Pubitemid 40165094)
30. Paone A, Starace D, Galli R, et al. Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-alpha-dependent mechanism. Carcinogenesis 2008;29:1334-42.
31. Park JH, Jeon DI, Yoon HE, et al. Poly I:C inhibits cell proliferation and enhances the growth inhibitory effect of paclitaxel in oral sqaumous cell carcinoma. Acta Odontologica Scandinavica 2011.
32. Peng S, Geng J, Sun R, et al. Polyinosinic-polycytidylic acid liposome induces human hepatoma cells apoptosis which correlates to the up-regulation of RIG-I like receptors. Cancer Science 2009;100:529-36.
33. Rydberg C, Mansson A, Uddman R, et al. Toll-like receptor agonists induce inflammation and cell death in a model of head and neck squamous cell carcinomas. Immunology 2009;128:e600-11.
34. Salaun B, Coste I, Rissoan MC, et al. TLR3 can directly trigger apoptosis in human cancer cells. Journal of Immunology 2006;176:4894-901.
35. Salaun B, Lebecque S, Matikainen S, et al. Toll-like receptor 3 expressed by melanoma cells as a target for therapy. Clinical Cancer Research 2007;13:4565-74. (Pubitemid 47219727)
36. Salaun B, Zitvogel L, Asselin-Paturel C, et al. TLR3 as a biomarker for the therapeutic efficacy of double-stranded RNA in breast cancer. Cancer Research 2011;71:1607-14.
37. Salem ML, Kadima AN, Cole DJ, et al. Defining the antigen-specific T-cell response to vaccination and poly(I:C)/TLR3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity. Journal of Immunotherapy 2005;28:220-8. (Pubitemid 40593987)
38. Schmidt C. Immune system's Toll-like receptors have good opportunity for cancer treatment. Journal of the National Cancer Institute 2006;98:574-5.
39. Schulz O, Diebold SS, Chen M, et al. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 2005;433:887-92.
40. Scully C, Bagan J. Oral squamous cell carcinoma overview. Oral Oncology 2009;45:301-8.
41. Scully C, Bedi R. Ethnicity and oral cancer. Lancet Oncology 2000;1:37-42.
42. Song EJ, Kang MJ, Kim YS, et al. Flagellin promotes the proliferation of gastric cancer cells via the Toll-like receptor 5. International Journal of Molecular Medicine 2011;28:115-9.
43. Sun R, Zhang Y, Lv Q, et al. Toll-like receptor 3 (TLR3) induces apoptosis via death receptors and mitochondria by up-regulating the transactivating p63 isoform {alpha} (TAP63{alpha}). Journal of Biological Chemistry 2011;286:15918-28.
44. Takaoka A, Hayakawa S, Yanai H, et al. Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 2003;424:516-23. (Pubitemid 36975769)
45. Umemura N, Zhu J, Mburu YK, et al. Defective NF-kappaB signaling in metastatic head and neck cancer cells leads to enhanced apoptosis by double-stranded RNA. Cancer Research 2012;72:45-55.
46. Weber A, Kirejczyk Z, Besch R, et al. Proapoptotic signalling through Toll-like receptor-3 involves TRIF-dependent activation of caspase-8 and is under the control of inhibitor of apoptosis proteins in melanoma cells. Cell Death and Differentiation 2010;17:942-51.
47. Wulff S, Pries R, Wollenberg B. Cytokine release of human NK cells solely triggered with poly I:C. Cellular Immunology 2010;263:135-7.
48. Zhou M, McFarland-Mancini MM, Funk HM, et al. Toll-like receptor expression in normal ovary and ovarian tumors. Cancer Immunology Immunotherapy 2009;58:1375-85.